Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Centene's Fidelis Care Buyout to Expand Presence in New York
by Zacks Equity Research
Centene's (CNC) acquisition of Fidelis Care for $3.75 billion for expanding in New York, is expected to impact Centene's top line and bottom line positively.
5 Discounted MedTech Stocks for a Healthy Portfolio
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
Universal Health (UHS) Grows on Buyouts, Expenses a Drag
by Zacks Equity Research
Despite solid revenue growth backed by inorganic strategies, Universal Health's (UHS) rising level of debt and expenses continue to weigh on margins.
Top Ranked Growth Stocks to Buy for September 11th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 11th:
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Ensign Group's Inorganic Growth Impresses, Debt Level Hurts
by Zacks Equity Research
Ensign Group's (ENSG) top line rises on inorganic and organic growth. Its financial health also impresses. However high level of costs and debts bother.
Molina Healthcare's Top Line Grows on Membership, Debts Hurt
by Zacks Equity Research
Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.
WellCare Health Partners Mission Health to Improve Offerings
by Zacks Equity Research
WellCare Health Plans, Inc's (WCG) subsidiary, Wellcare of North Carolina recently entered into an agreement with Mission Health to provide better Medicaid and Medicare services in North Carolina.
Centene (CNC) Poised to Grow on Buyouts, High Debt Bothers
by Zacks Equity Research
Centene's (CNC) accretive acquisitions backed by solid financials add to its top line. However, high debt and rising expenses hurt margins.
Amedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Tabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5%
by Zacks Equity Research
Tabula Rasa Healthcare, Inc. (TRHC) shares rose around 10% in the last trading session.
Aetna's (AET) $1 Billion Notes Due 2047 Rated By A.M Best
by Zacks Equity Research
Rating Giant A.M Bests assigned a Long-Term Issue Credit Rating of "bbb" to Aetna's (AET) $1 billion, 3.875% senior notes due to mature on Aug 15, 2047.
Envision Healthcare Hurt by High Debt, Increasing Expenses
by Zacks Equity Research
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Community Health Sells 2 Texas Units, Streamlines Business
by Zacks Equity Research
Community Health Systems, Inc.'s (CYH) subsidiaries have sold their ownership interest in two Texas hospitals and their associated assets to subsidiaries of HCA Healthcare.
Amedisys (AMED) Prospects Impressive Amid Tough Competition
by Zacks Equity Research
On Jun 5, we issued an updated research report on leading molecular diagnostic company, Amedisys, Inc. (AMED).
Why Is Amedisys (AMED) Up 4% Since the Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.
Healthcare Q1 Earnings Slated on May 2: AET, HCA & More
by Zacks Equity Research
The healthcare sector has been in the limelight since the change of power at the White House.